Keywords: Novartis, Exelon Patch, Alzheimer's disease, Higher dose, USA, FDA

FDA backs higher dose of Novartis Exelon Patch for Alzheimer's

Article | 04 September 2012

Print This

The US Food and Drug Administration has approved a higher dose of Swiss drug major Novartis’ (NOVN: VX) Exelon ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in